<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821535</url>
  </required_header>
  <id_info>
    <org_study_id>A4001084</org_study_id>
    <nct_id>NCT00821535</nct_id>
  </id_info>
  <brief_title>Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers</brief_title>
  <official_title>An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg
      maraviroc in healthy male Japanese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine maraviroc concentrations for pharmacokinetic analysis</measure>
    <time_frame>pre-48 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event monitoring</measure>
    <time_frame>Day 0 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bood pressure, pulse rate</measure>
    <time_frame>Day 0, Day 1, and Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood and urine safety laboratory tests</measure>
    <time_frame>Day 0 and Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Day 0 and Day 3</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Human Immunodeficiency Virus (HIV) Infection</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>maraviroc dosing group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc (Selzentry, Celsentri)</intervention_name>
    <description>12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.</description>
    <arm_group_label>Active group</arm_group_label>
    <other_name>Selzentry, Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male Japanese subjects between the ages of 21 and 50 years inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;45 kg.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Positive result for HIV, Hepatitis B surface antigen (HbsAg) or HCV antibody.

          -  Hypersensitivity/allergic reactions to any component of maraviroc, including soy
             lecithin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001084&amp;StudyName=Investigation%20Of%20Safety%20And%20Pharmacokinetics%20Following%20A%20Single%20Oral%20Dose%20Of%20300%20Mg%20Maraviroc%20In%20Healthy%20Male%20Japanese%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>November 15, 2010</last_update_submitted>
  <last_update_submitted_qc>November 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>pharmacokinetics, Japanese, healthy volunteer, maraviroc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

